{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:16:32Z","timestamp":1788383792183,"version":"build-2803163510"},"reference-count":256,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Cirrhosis is a severe form of liver fibrosis that results in the irreversible replacement of liver tissue with scar tissue in the liver. Environmental toxicity, infections, metabolic causes, or other genetic factors including autoimmune hepatitis can lead to chronic liver injury and can result in inflammation and fibrosis. This activates myofibroblasts to secrete ECM proteins, resulting in the formation of fibrous scars on the liver. Fibrosis regression is possible through the removal of pathophysiological causes as well as the elimination of activated myofibroblasts, resulting in the reabsorption of the scar tissue. To date, a wide range of antifibrotic therapies has been tried and tested, with varying degrees of success. These therapies include the use of growth factors, cytokines, miRNAs, monoclonal antibodies, stem-cell-based approaches, and other approaches that target the ECM. The positive results of preclinical and clinical studies raise the prospect of a viable alternative to liver transplantation in the near future. The present review provides a synopsis of recent antifibrotic treatment modalities for the treatment of liver cirrhosis, as well as a brief summary of clinical trials that have been conducted to date.<\/jats:p>","DOI":"10.3390\/cells11091500","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T16:49:57Z","timestamp":1651250997000},"page":"1500","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Recent Advancements in Antifibrotic Therapies for Regression of Liver Fibrosis"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5013-9439","authenticated-orcid":false,"given":"Anshika","family":"Jangra","sequence":"first","affiliation":[{"name":"Department of Research and Development, Cure Therapeutics Inc., Suwon 16506, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8764-8533","authenticated-orcid":false,"given":"Ashish","family":"Kothari","sequence":"additional","affiliation":[{"name":"Department of Microbiology, All India Institute of Medical Sciences, Rishikesh 249203, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phulen","family":"Sarma","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bikash","family":"Medhi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7805-2730","authenticated-orcid":false,"given":"Balram Ji","family":"Omar","sequence":"additional","affiliation":[{"name":"Department of Microbiology, All India Institute of Medical Sciences, Rishikesh 249203, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karanvir","family":"Kaushal","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, All India Institute of Medical Sciences, Rishikesh 249203, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-014-0145-y","article-title":"Liver cirrhosis mortality in 187 countries between 1980 and 2010: A systematic analysis","volume":"12","author":"Mokdad","year":"2014","journal-title":"BMC Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/tgh.2019.09.08","article-title":"Epidemiology of non-alcoholic and alcoholic fatty liver diseases","volume":"5","author":"Mitra","year":"2020","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/liv.13682","article-title":"Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening","volume":"38","author":"Marcellin","year":"2018","journal-title":"Liver Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1080\/15384101.2016.1152435","article-title":"Common pathway signature in lung and liver fibrosis","volume":"15","author":"Makarev","year":"2016","journal-title":"Cell Cycle"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: Therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Pardali, E., Sanchez-Duffhues, G., Gomez-Puerto, M.C., and Ten Dijke, P. (2017). TGF-\u03b2-induced endothelial-mesenchymal transition in fibrotic diseases. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18102157"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jhep.2017.10.020","article-title":"Clinical states of cirrhosis and competing risks","volume":"68","author":"Morabito","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_9","first-page":"281","article-title":"Pathophysiology of portal hypertension","volume":"18","author":"Iwakiri","year":"2014","journal-title":"Variceal Hemorrhage"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.12703\/P6-95","article-title":"Future therapy of portal hypertension in liver cirrhosis\u2013a guess","volume":"6","author":"Sauerbruch","year":"2014","journal-title":"F1000prime Rep."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Khanam, A., Saleeb, P.G., and Kottilil, S. (2021). Pathophysiology and Treatment Options for Hepatic Fibrosis: Can It Be Completely Cured?. Cells, 10.","DOI":"10.3390\/cells10051097"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.3389\/fphar.2021.671640","article-title":"Cellular Mechanisms of Liver Fibrosis","volume":"12","author":"Acharya","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"a005058","DOI":"10.1101\/cshperspect.a005058","article-title":"Extracellular matrix degradation and remodeling in development and disease","volume":"3","author":"Lu","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nrm3904","article-title":"Remodelling the extracellular matrix in development and disease","volume":"15","author":"Bonnans","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1369\/jhc.2010.955161","article-title":"Quantitative and qualitative alterations of heparan sulfate in fibrogenic liver diseases and hepatocellular cancer","volume":"58","author":"Egedi","year":"2010","journal-title":"J. Histochem. Cytochem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jhep.2015.02.039","article-title":"Hepatic fibrosis: Concept to treatment","volume":"62","author":"Trautwein","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5170402","DOI":"10.1155\/2016\/5170402","article-title":"Pathogenesis of nonalcoholic steatohepatitis: Interactions between liver parenchymal and nonparenchymal cells","volume":"2016","author":"Magee","year":"2016","journal-title":"BioMed Res. Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1172\/JCI93557","article-title":"Extracellular matrix as a driver of progressive fibrosis","volume":"128","author":"Herrera","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.bpg.2011.02.005","article-title":"Mechanisms of hepatic fibrogenesis","volume":"25","author":"Lee","year":"2011","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3748\/wjg.v26.i2.109","article-title":"Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C","volume":"26","author":"Tanwar","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jhep.2012.02.033","article-title":"Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy","volume":"57","author":"Peng","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jhep.2018.12.003","article-title":"Fibrosis and alcohol-related liver disease","volume":"70","author":"Lackner","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"10512","DOI":"10.3748\/wjg.v22.i48.10512","article-title":"Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets","volume":"22","author":"Zhang","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/livers1010002","article-title":"The Space of Disse: The Liver Hub in Health and Disease","volume":"1","author":"Nevzorova","year":"2021","journal-title":"Livers"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.immuni.2016.02.015","article-title":"Macrophages in tissue repair, regeneration, and fibrosis","volume":"44","author":"Wynn","year":"2016","journal-title":"Immunity"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Delgado, M.E., C\u00e1rdenas, B.I., Farran, N., and Fernandez, M. (2021). Metabolic Reprogramming of Liver Fibrosis. Cells, 10.","DOI":"10.3390\/cells10123604"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41232-016-0005-6","article-title":"Roles of hepatic stellate cells in liver inflammation: A new perspective","volume":"36","author":"Fujita","year":"2016","journal-title":"Inflamm. Regen."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"111572","DOI":"10.1016\/j.mad.2021.111572","article-title":"Hepatic stellate cell senescence in liver fibrosis: Characteristics, mechanisms and perspectives","volume":"199","author":"Zhang","year":"2021","journal-title":"Mech. Ageing Dev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"604894","DOI":"10.3389\/fmed.2021.604894","article-title":"Novel Immune Subsets and Related Cytokines: Emerging Players in the Progression of Liver Fibrosis","volume":"8","author":"Wan","year":"2021","journal-title":"Front. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/hep.25744","article-title":"Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice","volume":"56","author":"Kong","year":"2012","journal-title":"Hepatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/imm.13111","article-title":"Interleukin-9 blockage reduces early hepatic granuloma formation and fibrosis during Schistosoma japonicum infection in mice","volume":"158","author":"Zhan","year":"2019","journal-title":"Immunology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/hep.29782","article-title":"MAIT cells are chronically activated in patients with autoimmune liver disease and promote profibrogenic hepatic stellate cell activation","volume":"68","author":"Rombouts","year":"2018","journal-title":"Hepatology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.4049\/jimmunol.1203013","article-title":"IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation","volume":"191","author":"Tan","year":"2013","journal-title":"J. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1053\/j.gastro.2012.05.049","article-title":"Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice","volume":"143","author":"Meng","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-2893.2011.01561.x","article-title":"Increased Th17 cells contribute to disease progression in patients with HBV-associated liver cirrhosis","volume":"19","author":"Sun","year":"2012","journal-title":"J. Viral Hepat."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jss.2013.03.025","article-title":"Interleukin-17A plays a pivotal role in cholestatic liver fibrosis in mice","volume":"183","author":"Hara","year":"2013","journal-title":"J. Surg. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3892\/mmr.2016.5392","article-title":"Rapamycin ameliorates CCl4-induced liver fibrosis in mice through reciprocal regulation of the Th17\/Treg cell balance","volume":"14","author":"Gu","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"ref_39","first-page":"4883","article-title":"The JAK inhibitor tofacitinib ameliorates immune-mediated liver injury in mice","volume":"20","author":"Wang","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3389\/fimmu.2014.00450","article-title":"Mucosal-associated invariant T-cells: New players in anti-bacterial immunity","volume":"5","author":"Ussher","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_41","first-page":"1250","article-title":"Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17\u2013secreting T cells","volume":"117","author":"Dusseaux","year":"2011","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-04450-y","article-title":"Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver","volume":"9","author":"Hegde","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.4049\/jimmunol.174.2.1055","article-title":"CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangiocytes and hepatocytes within the inflamed human liver","volume":"174","author":"Heydtmann","year":"2005","journal-title":"J. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Geissmann, F., Cameron, T.O., Sidobre, S., Manlongat, N., Kronenberg, M., Briskin, M.J., Dustin, M.L., and Littman, D.R. (2005). Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol., 3.","DOI":"10.1371\/journal.pbio.0030113"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"40663","DOI":"10.1074\/jbc.C000761200","article-title":"Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages","volume":"275","author":"Shimaoka","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41586-019-1631-3","article-title":"Resolving the fibrotic niche of human liver cirrhosis at single-cell level","volume":"575","author":"Ramachandran","year":"2019","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/gut.48.4.548","article-title":"Apoptosis of hepatic stellate cells: Involvement in resolution of biliary fibrosis and regulation by soluble growth factors","volume":"48","author":"Issa","year":"2001","journal-title":"Gut"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/gast.2003.50013","article-title":"Histological outcome during long-term lamivudine therapy","volume":"124","author":"Dienstag","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S1665-2681(19)31740-5","article-title":"Reversibility of liver fibrosis","volume":"8","author":"Ramachandran","year":"2009","journal-title":"Ann. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1056\/NEJM200102083440604","article-title":"Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct","volume":"344","author":"Hammel","year":"2001","journal-title":"New Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"981","DOI":"10.7326\/0003-4819-127-11-199712010-00006","article-title":"Reversibility of hepatic fibrosis in autoimmune hepatitis","volume":"127","author":"Dufour","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0168-8278(86)80006-X","article-title":"Histological course of alcoholic hepatitis: Influence of abstinence, sex and extent of hepatic damage","volume":"2","author":"Bruguera","year":"1986","journal-title":"J. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/HMER.S9051","article-title":"Reversal of hepatic fibrosis: Pathophysiological basis of antifibrotic therapies","volume":"3","author":"Ismail","year":"2011","journal-title":"Hepatic Med. Evid. Res."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-Gea, V. (2016). Liver Fibrosis: What Is Reversible and What Not? How to Assess Regression. Portal Hypertension VI, Springer.","DOI":"10.1007\/978-3-319-23018-4_14"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.3748\/wjg.v23.i18.3228","article-title":"Platelets in liver disease, cancer and regeneration","volume":"23","author":"Kurokawa","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Baranova, A., Lal, P., Birerdinc, A., and Younossi, Z.M. (2011). Non-invasive markers for hepatic fibrosis. BMC Gastroenterol., 11.","DOI":"10.1186\/1471-230X-11-91"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3389\/fphar.2016.00159","article-title":"Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy?","volume":"7","author":"Chin","year":"2016","journal-title":"Front. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1172\/JCI66028","article-title":"Evolving therapies for liver fibrosis","volume":"123","author":"Schuppan","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"FSO250","DOI":"10.4155\/fsoa-2017-0083","article-title":"Liver fibrosis: A compilation on the biomarkers status and their significance during disease progression","volume":"4","author":"Nallagangula","year":"2018","journal-title":"Future Sci. OA"},{"key":"ref_60","first-page":"67","article-title":"Serum Marker Panels for Predicting Liver Fibrosis\u2013An Update","volume":"41","author":"Joseph","year":"2020","journal-title":"Clin. Biochem. Rev."},{"key":"ref_61","first-page":"218","article-title":"Non-invasive assessment of liver fibrosis","volume":"25","author":"Papastergiou","year":"2012","journal-title":"Ann. Gastroenterol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4297206","DOI":"10.1155\/2017\/4297206","article-title":"Cytokines genotype-phenotype correlation in nonalcoholic steatohepatitis","volume":"2017","author":"Bocsan","year":"2017","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Hall, R.A., Liebe, R., Hochrath, K., Kazakov, A., Alberts, R., Laufs, U., Bohm, M., Fischer, H.P., Williams, R.W., and Schughart, K. (2014). Systems genetics of liver fibrosis: Identification of fibrogenic and expression quantitative trait loci in the BXD murine reference population. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0089279"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"19396","DOI":"10.1038\/s41598-021-98806-y","article-title":"Single-cell and bulk transcriptomics of the liver reveals potential targets of NASH with fibrosis","volume":"11","author":"Wang","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Krenkel, O., Hundertmark, J., Ritz, T.P., Weiskirchen, R., and Tacke, F. (2019). Single Cell RNA Sequencing Identifies Subsets of Hepatic Stellate Cells and Myofibroblasts in Liver Fibrosis. Cells, 8.","DOI":"10.3390\/cells8050503"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"676349","DOI":"10.3389\/fmolb.2021.676349","article-title":"A Cross-Platform Metabolomics Comparison Identifies Serum Metabolite Signatures of Liver Fibrosis Progression in Chronic Hepatitis C Patients","volume":"8","author":"Shanmuganathan","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fonc.2018.00024","article-title":"Multifaceted role of the urokinase-type plasminogen activator (uPA) and its receptor (uPAR): Diagnostic, prognostic, and therapeutic applications","volume":"8","author":"Mahmood","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jcmgh.2017.04.007","article-title":"Epigenetics and Liver Fibrosis","volume":"4","author":"Mann","year":"2017","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jceh.2018.02.001","article-title":"Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD) as Serological Fibrosis Marker","volume":"9","author":"Akdogan","year":"2019","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1478-3231.2011.02665.x","article-title":"Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis","volume":"32","author":"Zimmermann","year":"2012","journal-title":"Liver Int."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Garnaes, E., Mortensen, C., Hobolth, L., Andersen, O., Nehlin, J., and Moller, S. (2019). Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0220697"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"S-680","DOI":"10.1016\/S0016-5085(15)32295-2","article-title":"Mo1351 Systemic Levels of Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Predict the Severity of Acute Alcohol Pancreatitis","volume":"148","author":"Nikkola","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/liv.12705","article-title":"Serum soluble urokinase plasminogen activator receptor as a screening test for the early diagnosis of hepatocellular carcinoma","volume":"35","author":"Chounta","year":"2015","journal-title":"Liver Int."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Radu-Ionita, F., Pyrsopoulos, N.T., Jinga, M., Tintoiu, I.C., Sun, Z., and Bontas, E. (2020). Liver Diseases: A Multidisciplinary Textbook, Springer Nature.","DOI":"10.1007\/978-3-030-24432-3"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jhep.2013.12.026","article-title":"Biomarkers of liver cell death","volume":"60","author":"Eguchi","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/joim.12054","article-title":"Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality","volume":"274","author":"Zimmermann","year":"2013","journal-title":"J. Intern. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/MPA.0000000000000730","article-title":"Plasma Level of Soluble Urokinase-type Plasminogen Activator Receptor Predicts the Severity of Acute Alcohol Pancreatitis","volume":"46","author":"Nikkola","year":"2017","journal-title":"Pancreas"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3389\/fimmu.2017.00403","article-title":"Dual role of Fas\/FasL-mediated signal in peripheral immune tolerance","volume":"8","author":"Yamada","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-020-03003-w","article-title":"Understanding lipotoxicity in NAFLD pathogenesis: Is CD36 a key driver?","volume":"11","author":"Rada","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_80","first-page":"3905130","article-title":"Gut Microbiota and Liver Fibrosis: One Potential Biomarker for Predicting Liver Fibrosis","volume":"2020","author":"Li","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.cmet.2020.06.005","article-title":"A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis","volume":"32","author":"Oh","year":"2020","journal-title":"Cell Metab."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/s41467-019-09455-9","article-title":"A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease","volume":"10","author":"Caussy","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1194\/jlr.R024794","article-title":"Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease: Thematic review series: New lipid and lipoprotein targets for the treatment of cardiometabolic diseases","volume":"53","author":"Porez","year":"2012","journal-title":"J. Lipid Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/aps.2014.116","article-title":"Farnesoid X receptor: A master regulator of hepatic triglyceride and glucose homeostasis","volume":"36","author":"Jiao","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"New Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/hep.27744","article-title":"Fibrates and cholestasis","volume":"62","author":"Ghonem","year":"2015","journal-title":"Hepatology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"304","DOI":"10.14218\/JCTH.2020.00023","article-title":"Antihepatic fibrosis drugs in clinical trials","volume":"8","author":"Guo","year":"2020","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/hep4.1057","article-title":"The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis","volume":"1","author":"Wettstein","year":"2017","journal-title":"Hepatol. Commun."},{"key":"ref_92","unstructured":"University Hospital Southampton NHS Foundation Trust, and National Institute for Health Research, UK (2022, January 25). Treatment of Non Alcoholic Fatty Liver Disease With n-3 Fatty Acids, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT00760513."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.nutres.2014.09.005","article-title":"Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease","volume":"34","author":"Faghihzadeh","year":"2014","journal-title":"Nutr. Res."},{"key":"ref_94","unstructured":"(2022, January 24). The Effects of Resveratrol Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT02030977."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2021.10.029","article-title":"Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study","volume":"76","author":"Rinella","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"105803","DOI":"10.1016\/j.cct.2019.06.017","article-title":"REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis","volume":"84","author":"Ratziu","year":"2019","journal-title":"Contemp. Clin. Trials"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: Semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging","volume":"54","author":"Flint","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3904\/kjim.2017.317","article-title":"Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension","volume":"33","author":"Shim","year":"2018","journal-title":"Korean J. Intern. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"G726","DOI":"10.1152\/ajpgi.00162.2009","article-title":"Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C","volume":"297","author":"Colmenero","year":"2009","journal-title":"Am. J. Physiol. -Gastrointest. Liver Physiol."},{"key":"ref_100","unstructured":"(2022, February 13). Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT00298714."},{"key":"ref_101","unstructured":"Yonsei, U. (2022, February 13). Effect of Candesartan in Alcoholic Liver Fibrosis, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT00990639."},{"key":"ref_102","unstructured":"Sherief, A.-E., and Tanta, U. (2022, February 13). Effect of Some Drugs on Liver Fibrosis, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03770936."},{"key":"ref_103","unstructured":"(2022, February 22). Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT00265642."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"730176","DOI":"10.3389\/fcell.2021.730176","article-title":"Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy","volume":"9","author":"Tan","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bbrc.2018.02.067","article-title":"Synergistic effects of simvastatin and bone marrow-derived mesenchymal stem cells on hepatic fibrosis","volume":"497","author":"Jang","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: A randomized controlled trial","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_107","unstructured":"(2022, February 13). Efficacy of Simvastatin in Alcoholic Liver Fibrosis, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04971577."},{"key":"ref_108","unstructured":"Merck, S., and Dohme, C. (2022, February 13). Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED), Available online: https:\/\/ClinicalTrials.gov\/show\/NCT00049842."},{"key":"ref_109","unstructured":"Merck, S., and Dohme, C. (2022, January 13). PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00039871."},{"key":"ref_110","unstructured":"RWTH Aachen University, and Hannover Medical School (2022, January 13). Induction of Fibrosis Regression on Patients With Chronic Hepatitis B Infection, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT01341106."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.23785","article-title":"Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B","volume":"52","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"ref_112","unstructured":"Peking University People\u2019s Hospital, RenJi Hospital, Peking University, Shanghai Zhongshan Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Public Health Clinical Center, Nanfang Hospital of Southern Medical University, Sir Run Run Shaw Hospital, Beijing YouAn Hospital, and Peking University First Hospital (2022, February 13). Optimized Treatment and Regression of HBV-induced Liver Fibrosis, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT01938781."},{"key":"ref_113","unstructured":"Judit Pich, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (2022, February 22). Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03780673."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/hep.23123","article-title":"Targeting liver fibrosis: Strategies for development and validation of antifibrotic therapies","volume":"50","author":"Popov","year":"2009","journal-title":"Hepatology"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"12719","DOI":"10.1073\/pnas.96.22.12719","article-title":"In vivo inhibition of rat stellate cell activation by soluble transforming growth factor \u03b2 type II receptor: A potential new therapy for hepatic fibrosis","volume":"96","author":"George","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1007\/s10620-018-5168-3","article-title":"A COL1A1 promoter-controlled expression of TGF-\u03b2 soluble receptor inhibits hepatic fibrosis without triggering autoimmune responses","volume":"63","author":"Zhang","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1172\/JCI30740","article-title":"Inhibition of TGF-\u03b2 with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression","volume":"117","author":"Biswas","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1038\/mtna.2014.7","article-title":"Targeting TGF-\u03b2 signaling by antisense oligonucleotide-mediated knockdown of TGF-\u03b2 type I receptor","volume":"3","author":"Kemaladewi","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3810","article-title":"Targeting the TGF\u03b2 signalling pathway in disease","volume":"11","author":"Akhurst","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/art.22289","article-title":"Recombinant human anti\u2013transforming growth factor \u03b21 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I\/II trial of CAT-192","volume":"56","author":"Denton","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Zhang, X., Yun, J.S., Han, D., Yook, J.I., Kim, H.S., and Cho, E.S. (2020). TGF-\u03b2 pathway in salivary gland fibrosis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239138"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1440-1746.1993.tb01544.x","article-title":"Clinical evaluation of serum tissue inhibitor of metalloproteinases-1 levels in patients with liver diseases","volume":"8","author":"Muzzillo","year":"1993","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1096\/fj.05-4828com","article-title":"Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice","volume":"20","author":"Roderfeld","year":"2006","journal-title":"FASEB J."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1242\/jcs.108.6.2241","article-title":"Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling","volume":"108","author":"Breuss","year":"1995","journal-title":"J. Cell Sci."},{"key":"ref_125","unstructured":"(2022, February 22). Biogen STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF), Available online: https:\/\/ClinicalTrials.gov\/show\/NCT01371305."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1053\/j.gastro.2008.04.009","article-title":"Inhibition of integrin \u03b1v\u03b26 on cholangiocytes blocks transforming growth factor-\u03b2 activation and retards biliary fibrosis progression","volume":"135","author":"Patsenker","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/TP.0b013e3182884866","article-title":"Role of integrin \u03b1v\u03b26 in the pathogenesis of ischemia-related biliary fibrosis after liver transplantation","volume":"95","author":"Chen","year":"2013","journal-title":"Transplantation"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"7640","DOI":"10.1158\/0008-5472.CAN-10-0824","article-title":"Hepatocyte nuclear factor 4\u03b1 suppresses the development of hepatocellular carcinoma","volume":"70","author":"Ning","year":"2010","journal-title":"Cancer Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1136\/gut.2008.174904","article-title":"Hepatocyte nuclear factor 4\u03b1 attenuates hepatic fibrosis in rats","volume":"59","author":"Yue","year":"2010","journal-title":"Gut"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Weber, S.N., Bohner, A., Dapito, D.H., Schwabe, R.F., and Lammert, F. (2016). TLR4 deficiency protects against hepatic fibrosis and diethylnitrosamine-induced pre-carcinogenic liver injury in fibrotic liver. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0158819"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nm1589","article-title":"Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists","volume":"13","author":"Kanzler","year":"2007","journal-title":"Nat. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jhep.2021.08.011","article-title":"Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model","volume":"75","author":"Yang","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.chest.2018.08.1058","article-title":"Randomized, double-blind, placebo-controlled, phase 2 trial of BMS-986020, a lysophosphatidic acid receptor antagonist for the treatment of idiopathic pulmonary fibrosis","volume":"154","author":"Palmer","year":"2018","journal-title":"Chest"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc1143","article-title":"The emerging role of lysophosphatidic acid in cancer","volume":"3","author":"Mills","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.7150\/jca.41841","article-title":"Lysophosphatidic acid receptors: Biochemical and clinical implications in different diseases","volume":"11","author":"Xiang","year":"2020","journal-title":"J. Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1111\/j.1476-5381.2010.00828.x","article-title":"A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model","volume":"160","author":"Swaney","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/hep.24485","article-title":"Tumor-secreted lysophostatidic acid accelerates hepatocellular carcinoma progression by promoting differentiation of peritumoral fibroblasts in myofibroblasts","volume":"54","author":"Mazzocca","year":"2011","journal-title":"Hepatology"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"588","DOI":"10.2183\/pjab.86.588","article-title":"The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine","volume":"86","author":"Nakamura","year":"2010","journal-title":"Proc. Jpn. Acad. Ser. B"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"7072","DOI":"10.2741\/3211","article-title":"HGF as a renotrophic and anti-fibrotic regulator in chronic renal disease","volume":"13","author":"Mizuno","year":"2008","journal-title":"Front. Biosci."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2217\/17460751.2.2.161","article-title":"Hepatocyte growth factor: A regenerative drug for acute hepatitis and liver cirrhosis","volume":"2","author":"Mizuno","year":"2007","journal-title":"Regen. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"F134","DOI":"10.1152\/ajprenal.00199.2003","article-title":"Suppressions of chronic glomerular injuries and TGF-\u03b21 production by HGF in attenuation of murine diabetic nephropathy","volume":"286","author":"Mizuno","year":"2004","journal-title":"Am. J. Physiol. -Ren. Physiol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"H2131","DOI":"10.1152\/ajpheart.01239.2003","article-title":"Hepatocyte growth factor prevents tissue fibrosis, remodeling, and dysfunction in cardiomyopathic hamster hearts","volume":"288","author":"Nakamura","year":"2005","journal-title":"Am. J. Physiol. -Heart Circ. Physiol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1369\/0022155415627681","article-title":"TGF-\u03b2\/SMAD pathway and its regulation in hepatic fibrosis","volume":"64","author":"Xu","year":"2016","journal-title":"J. Histochem. Cytochem."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fj.04-1535fje","article-title":"HGF reduces advancing lung fibrosis in mice: A potential role for MMP-dependent myofibroblast apoptosis","volume":"19","author":"Mizuno","year":"2005","journal-title":"FASEB J."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0002-9440(10)62323-1","article-title":"Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis","volume":"166","author":"Kim","year":"2005","journal-title":"Am. J. Pathol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/hep.24796","article-title":"Hepatocyte growth factor\/c-met signaling is required for stem-cell\u2013mediated liver regeneration in mice","volume":"55","author":"Ishikawa","year":"2012","journal-title":"Hepatology"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1386-6346(03)00115-3","article-title":"Connective tissue growth factor (CTGF\/CCN2) in hepatic fibrosis","volume":"26","author":"Rachfal","year":"2003","journal-title":"Hepatol. Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/hep.23102","article-title":"Susceptibility to liver fibrosis in mice expressing a connective tissue growth factor transgene in hepatocytes","volume":"50","author":"Tong","year":"2009","journal-title":"Hepatology"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1681\/ASN.2007030290","article-title":"PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis","volume":"19","author":"Eitner","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0002-9440(10)63694-2","article-title":"Transgenic overexpression of platelet-derived growth factor-C in the mouse heart induces cardiac fibrosis, hypertrophy, and dilated cardiomyopathy","volume":"163","author":"Li","year":"2003","journal-title":"Am. J. Pathol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/35010579","article-title":"PDGF-C is a new protease-activated ligand for the PDGF \u03b1-receptor","volume":"2","author":"Li","year":"2000","journal-title":"Nat. Cell Biol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1073\/pnas.0409722102","article-title":"Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma","volume":"102","author":"Campbell","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.3892\/mmr.2013.1719","article-title":"Interleukin-1\u03b2 upregulates matrix metalloproteinase-13 gene expression via c-Jun N-terminal kinase and p38 MAPK pathways in rat hepatic stellate cells","volume":"8","author":"Tang","year":"2013","journal-title":"Mol. Med. Rep."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/jvh.12226","article-title":"Acute and chronic immune biomarker changes during interferon\/ribavirin treatment in HIV\/HCV co-infected patients","volume":"22","author":"Jain","year":"2015","journal-title":"J. Viral Hepat."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1158\/0008-5472.CAN-12-0028","article-title":"Acyclic retinoid targets platelet-derived growth factor signaling in the prevention of hepatic fibrosis and hepatocellular carcinoma development","volume":"72","author":"Okada","year":"2012","journal-title":"Cancer Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.it.2009.12.001","article-title":"The immunology of fibrosis: Innate and adaptive responses","volume":"31","author":"Wick","year":"2010","journal-title":"Trends Immunol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.3389\/fimmu.2020.574276","article-title":"Immunomodulatory role of the extracellular matrix within the liver disease microenvironment","volume":"11","author":"McQuitty","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/hep.27332","article-title":"Hepatic inflammation and fibrosis: Functional links and key pathways","volume":"61","author":"Seki","year":"2015","journal-title":"Hepatology"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.1016\/S0021-9258(18)53232-4","article-title":"Transcriptional regulation of TSG6, a tumor necrosis factor-and interleukin-1-inducible primary response gene coding for a secreted hyaluronan-binding protein","volume":"268","author":"Lee","year":"1993","journal-title":"J. Biol. Chem."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"15354","DOI":"10.1074\/jbc.M110765200","article-title":"A novel allelic variant of the human TSG-6 gene encoding an amino acid difference in the CUB module: Chromosomal localization, frequency analysis, modeling, and expression","volume":"277","author":"Nentwich","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_162","first-page":"1982","article-title":"Isolation and characterization of eight tumor necrosis factor-induced gene sequences from human fibroblasts","volume":"10","author":"Lee","year":"1990","journal-title":"Mol. Cell. Biol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1083\/jcb.116.2.545","article-title":"A novel secretory tumor necrosis factor-inducible protein (TSG-6) is a member of the family of hyaluronate binding proteins, closely related to the adhesion receptor CD44","volume":"116","author":"Lee","year":"1992","journal-title":"J. Cell Biol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1002\/art.10555","article-title":"Cartilage-specific constitutive expression of TSG-6 protein (product of tumor necrosis factor \u03b1\u2013stimulated gene 6) provides a chondroprotective, but not antiinflammatory, effect in antigen-induced arthritis","volume":"46","author":"Glant","year":"2002","journal-title":"Arthritis Rheum."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1242\/jcs.00407","article-title":"TSG-6: A multifunctional protein associated with inflammation","volume":"116","author":"Milner","year":"2003","journal-title":"J. Cell Sci."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/mt.2011.211","article-title":"Mesenchymal stem\/stromal cells (MSCs): Role as guardians of inflammation","volume":"20","author":"Prockop","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"119375","DOI":"10.1016\/j.biomaterials.2019.119375","article-title":"Tumor necrosis factor-inducible gene 6 reprograms hepatic stellate cells into stem-like cells, which ameliorates liver damage in mouse","volume":"219","author":"Wang","year":"2019","journal-title":"Biomaterials"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3389\/fphar.2020.00010","article-title":"TSG-6 Inhibits Oxidative Stress and Induces M2 Polarization of Hepatic Macrophages in Mice With Alcoholic Hepatitis via Suppression of STAT3 Activation","volume":"11","author":"Wan","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3389\/fcell.2021.645593","article-title":"Mechanisms of cellular senescence: Cell cycle arrest and senescence associated secretory phenotype","volume":"9","author":"Kumari","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","article-title":"The senescence-associated secretory phenotype: The dark side of tumor suppression","volume":"5","author":"Desprez","year":"2010","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1101\/gad.302570.117","article-title":"Identification of senescent cell surface targetable protein DPP4","volume":"31","author":"Kim","year":"2017","journal-title":"Genes Dev."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1111\/febs.15282","article-title":"The ECM path of senescence in aging: Components and modifiers","volume":"287","author":"Levi","year":"2020","journal-title":"FEBS J."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/JLB.MR0718-299R","article-title":"Senescent cells: Living or dying is a matter of NK cells","volume":"105","author":"Antonangeli","year":"2019","journal-title":"J. Leukoc. Biol."},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Rossi, M., and Abdelmohsen, K. (2021). The Emergence of Senescent Surface Biomarkers as Senotherapeutic Targets. Cells, 10.","DOI":"10.3390\/cells10071740"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc3930","article-title":"Building better monoclonal antibody-based therapeutics","volume":"15","author":"Weiner","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: A therapeutic target for CT-011, a novel monoclonal anti\u2013PD-1 antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"key":"ref_178","first-page":"297","article-title":"Interleukins in chronic liver disease: Lessons learned from experimental mouse models","volume":"7","author":"Hammerich","year":"2014","journal-title":"Clin. Exp. Gastroenterol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4110\/in.2016.16.3.147","article-title":"The immune landscape in nonalcoholic steatohepatitis","volume":"16","author":"Narayanan","year":"2016","journal-title":"Immune Netw."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4049\/jimmunol.162.1.299","article-title":"IL-2 induces STAT4 activation in primary NK cells and NK cell lines, but not in T cells","volume":"162","author":"Wang","year":"1999","journal-title":"J. Immunol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/hep.510310123","article-title":"Increased toxin-induced liver injury and fibrosis in interleukin-6\u2013deficient mice","volume":"31","author":"Kovalovich","year":"2000","journal-title":"Hepatology"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/hep.510280620","article-title":"Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis","volume":"28","author":"Thompson","year":"1998","journal-title":"Hepatology"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/hep.510280621","article-title":"Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice","volume":"28","author":"Louis","year":"1998","journal-title":"Hepatology"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.4049\/jimmunol.161.8.4201","article-title":"IFN-\u03b3, IL-12, and TNF-\u03b1 are required to maintain reduced liver pathology in mice vaccinated with Schistosoma mansoni eggs and IL-12","volume":"161","author":"Hoffmann","year":"1998","journal-title":"J. Immunol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1172\/JCI0215950","article-title":"IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells","volume":"110","author":"Parihar","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_186","first-page":"879","article-title":"Interleukin-15 enhances cytotoxicity, receptor expression, and expansion of neonatal natural killer cells in long-term culture","volume":"11","author":"Choi","year":"2004","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/hep.23837","article-title":"Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: Role of signal transducer and activator of transcription 3","volume":"52","author":"Ki","year":"2010","journal-title":"Hepatology"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jhep.2010.03.004","article-title":"Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22","volume":"53","author":"Yang","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"eaar7754","DOI":"10.1126\/sciimmunol.aar7754","article-title":"Type 3 cytokines IL-17A and IL-22 drive TGF-\u03b2\u2013dependent liver fibrosis","volume":"3","author":"Fabre","year":"2018","journal-title":"Sci. Immunol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/hep.27392","article-title":"IL-30 (IL27p28) attenuates liver fibrosis through inducing NKG2D-rae1 interaction between NKT and activated hepatic stellate cells in mice","volume":"60","author":"Mitra","year":"2014","journal-title":"Hepatology"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.3389\/fimmu.2018.02452","article-title":"Unraveling SSc Pathophysiology; The Myofibroblast","volume":"9","author":"Vonk","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_192","first-page":"988","article-title":"Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts","volume":"292","author":"Fedarko","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/jid.2012.463","article-title":"IL-22 promotes fibroblast-mediated wound repair in the skin","volume":"133","author":"McGee","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1067\/mai.2001.114702","article-title":"IL-4 and IL-13 induce myofibroblastic phenotype of human lung fibroblasts through c-Jun NH2-terminal kinase\u2013dependent pathway","volume":"107","author":"Hashimoto","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"36099","DOI":"10.1074\/jbc.M505291200","article-title":"Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2","volume":"280","author":"Theiss","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1001\/jamaoto.2017.0977","article-title":"Interferon-\u03b3 treatment of human laryngotracheal stenosis\u2013derived fibroblasts","volume":"143","author":"Motz","year":"2017","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/art.1780290706","article-title":"Inhibition of excessive scleroderma fibroblast collagen production by recombinant \u03b3-interferon: Association with a coordinate decrease in types I and III procollagen messenger RNA levels","volume":"29","author":"Rosenbloom","year":"1986","journal-title":"Arthritis Rheum. Off. J. Am. Coll. Rheumatol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000073718","article-title":"Potential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro","volume":"132","author":"Saito","year":"2003","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10975","article-title":"Exploiting a natural conformational switch to engineer an interleukin-2 \u2018superkine\u2019","volume":"484","author":"Levin","year":"2012","journal-title":"Nature"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.4049\/jimmunol.180.4.2099","article-title":"Preassociation of IL-15 with IL-15R\u03b1-IgG1-Fc enhances its activity on proliferation of NK and CD8+\/CD44high T cells and its antitumor action","volume":"180","author":"Dubois","year":"2008","journal-title":"J. Immunol."},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Lehmann, D., Spanholtz, J., Sturtzel, C., Tordoir, M., Schlechta, B., Groenewegen, D., and Hofer, E. (2014). IL-12 directs further maturation of ex vivo differentiated NK cells with improved therapeutic potential. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087131"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"I13","DOI":"10.1186\/1479-5876-8-S1-I13","article-title":"Chemokines as inflammatory mediators of fibrosis in liver fibrosis","volume":"8","author":"Wasmuth","year":"2010","journal-title":"J. Transl. Med."},{"key":"ref_204","first-page":"310","article-title":"CXCR3, Inflammation, and autoimmune diseases","volume":"1173","author":"Lacotte","year":"2009","journal-title":"Contemp. Challenge Autoimmun."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.12688\/f1000research.26728.1","article-title":"Potential therapeutic manipulations of the CXCR3 chemokine axis for the treatment of inflammatory fibrosing diseases","volume":"9","author":"Groover","year":"2020","journal-title":"F1000Research"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13578-017-0161-7","article-title":"The roles of microRNA families in hepatic fibrosis","volume":"7","author":"Jiang","year":"2017","journal-title":"Cell Biosci."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.3892\/or.2014.3036","article-title":"Diverse roles of miR-29 in cancer","volume":"31","author":"Jiang","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Kitano, M., and Bloomston, P.M. (2016). Hepatic stellate cells and microRNAs in pathogenesis of liver fibrosis. J. Clin. Med., 5.","DOI":"10.3390\/jcm5030038"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/infdis\/jir186","article-title":"Hepatitis C virus infection and hepatic stellate cell activation downregulate miR-29: miR-29 overexpression reduces hepatitis C viral abundance in culture","volume":"203","author":"Bandyopadhyay","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_210","doi-asserted-by":"crossref","unstructured":"Kwiecinski, M., Noetel, A., Elfimova, N., Trebicka, J., Schievenbusch, S., Strack, I., Molnar, L., von Brandenstein, M., T\u00f6x, U., and Nischt, R. (2011). Hepatocyte growth factor (HGF) inhibits collagen I and IV synthesis in hepatic stellate cells by miRNA-29 induction. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0024568"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.bbrc.2009.11.056","article-title":"Suppression of type I collagen production by microRNA-29b in cultured human stellate cells","volume":"391","author":"Ogawa","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Huang, Y.-H., Tiao, M.-M., Huang, L.-T., Chuang, J.-H., Kuo, K.-C., Yang, Y.-L., and Wang, F.-S. (2015). Activation of Mir-29a in activated hepatic stellate cells modulates its profibrogenic phenotype through inhibition of histone deacetylases 4. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0136453"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.bbrc.2014.03.037","article-title":"MiR-29b inhibits collagen maturation in hepatic stellate cells through down-regulating the expression of HSP47 and lysyl oxidase","volume":"446","author":"Zhang","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1667\/RR13784.1","article-title":"The miR-15 family enhances the radiosensitivity of breast cancer cells by targeting G2 checkpoints","volume":"183","author":"Mei","year":"2015","journal-title":"Radiat. Res."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3727\/096504016X14611963142290","article-title":"MicroRNA-15a inhibits proliferation and induces apoptosis in CNE1 nasopharyngeal carcinoma cells","volume":"24","author":"Zhu","year":"2016","journal-title":"Oncol. Res."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1136\/gutjnl-2020-322526","article-title":"MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases","volume":"70","author":"Wang","year":"2021","journal-title":"Gut"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3389\/fphys.2018.01297","article-title":"Increased expression of resistin in microRNA-155-deficient white adipose tissues may be a possible driver of metabolically healthy obesity transition to classical obesity","volume":"9","author":"Johnson","year":"2018","journal-title":"Front. Physiol."},{"key":"ref_218","first-page":"3008","article-title":"MicroRNA-34a promotes hepatic stellate cell activation via targeting ACSL1","volume":"21","author":"Yan","year":"2015","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.intimp.2016.09.011","article-title":"Fine-tuning the expression of microRNA-155 controls acetaminophen-induced liver inflammation","volume":"40","author":"Yuan","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/hep.26768","article-title":"Epigenetic regulation of connective tissue growth factor by MicroRNA-214 delivery in exosomes from mouse or human hepatic stellate cells","volume":"59","author":"Chen","year":"2014","journal-title":"Hepatology"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.7150\/ijbs.58365","article-title":"MicroRNA-223 restricts liver fibrosis by inhibiting the TAZ-IHH-GLI2 and PDGF signaling pathways via the crosstalk of multiple liver cell types","volume":"17","author":"Wang","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2174\/157488807782793763","article-title":"Mesenchymal stromal cells from umbilical cord blood","volume":"2","author":"Bieback","year":"2007","journal-title":"Curr. Stem Cell Res. Ther."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/QAD.0000000000000263","article-title":"Natural killer cell and T-cell subset distributions and activation influence susceptibility to perinatal HIV-1 infection","volume":"28","author":"Gasper","year":"2014","journal-title":"AIDS"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fimmu.2017.00329","article-title":"Umbilical cord blood natural killer cells, their characteristics, and potential clinical applications","volume":"8","author":"Sarvaria","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0301-472X(03)00110-3","article-title":"HLA expression and immunologic propertiesof differentiated and undifferentiated mesenchymal stem cells","volume":"31","author":"Tammik","year":"2003","journal-title":"Exp. Hematol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1042\/CBI20090386","article-title":"Mesenchymal stem cell infusion therapy in a carbon tetrachloride-induced liver fibrosis model affects matrix metalloproteinase expression","volume":"34","author":"Rabani","year":"2010","journal-title":"Cell Biol. Int."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12876-014-0198-6","article-title":"Effect of bone marrow-derived mesenchymal stem cells on hepatic fibrosis in a thioacetamide-induced cirrhotic rat model","volume":"14","author":"Jang","year":"2014","journal-title":"BMC Gastroenterol."},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"Fathy, M., Okabe, M., Saad Eldien, H.M., and Yoshida, T. (2020). AT-MSCs antifibrotic activity is improved by eugenol through modulation of TGF-\u03b2\/Smad signaling pathway in rats. Molecules, 25.","DOI":"10.3390\/molecules25020348"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-020-01655-1","article-title":"Ultrasound-targeted microbubble destruction optimized HGF-overexpressing bone marrow stem cells to repair fibrotic liver in rats","volume":"11","author":"Sun","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"ref_230","first-page":"7182","article-title":"Effects of bone marrow-derived mesenchymal stem cells on hypoxia and the transforming growth factor beta 1 (TGF\u03b2-1) and SMADs pathway in a mouse model of cirrhosis","volume":"25","author":"Zhang","year":"2019","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"7227","DOI":"10.3892\/mmr.2015.4362","article-title":"Bone marrow-derived mesenchymal stem cells inhibit the proliferation of hepatic stellate cells by inhibiting the transforming growth factor \u03b2 pathway","volume":"12","author":"Zhang","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.3390\/ijms15047004","article-title":"Human bone marrow mesenchymal stem cell-derived hepatocytes improve the mouse liver after acute acetaminophen intoxication by preventing progress of injury","volume":"15","author":"Stock","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_233","unstructured":"Asian Institute of Gastroenterology, India (2022, February 22). Combination of Autologous MSC and HSC Infusion in Patients With Decompensated Cirrhosis, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04243681."},{"key":"ref_234","unstructured":"Ukraine Association of Biobank (2022, February 22). Long Term Follow up Mesenchymal Stem Cell Therapy for Patients Virus-related Liver Cirrhosis, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT05080465."},{"key":"ref_235","unstructured":"Sun Yat-Sen University, and Third Affiliated Hospital, Sun Yat-Sen University (2022, January 13). Autologous Bone Marrow Mesenchymal Stem Cells Transplantation Via Hepatic Artery in Patients With Liver Cirrhosis, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT00976287."},{"key":"ref_236","unstructured":"S-Evans Biosciences Co., Ltd., Zhejiang University, Zhejiang General Hospital of Armed Police, Zhenjiang First People\u2019s Hospital, and Wuhan General Hospital of Guangzhou Military Command (2022, January 20). Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT01483248."},{"key":"ref_237","unstructured":"Alliancells Bioscience Corporation Limited (2022, January 13). Safety and Efficacy Study of Umbilical Mesenchymal Stem Cells for Liver Cirrhosis, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT01573923."},{"key":"ref_238","unstructured":"Chaitanya Hospital, Pune (2022, February 23). A Clinical Study to Evaluate the Safety and Efficacy of Mesenchymal Stem Cells in Liver Cirrhosis, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT01877759."},{"key":"ref_239","unstructured":"Shenzhen Beike Bio-Technology Co., Ltd., and No.85 Hospital, Changning, Shanghai, China (2022, February 23). Human Umbilical Cord Mesenchymal Stem Cells Transplantation for Patients With Decompensated Liver Cirrhosis, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT01342250."},{"key":"ref_240","unstructured":"Rohto Pharmaceutical Co., Ltd (2022, February 23). A Study of ADR-001 in Patients With Liver Cirrhosis, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03254758."},{"key":"ref_241","unstructured":"Shahid Beheshti University of Medical Sciences, and Tarbiat Modarres University (2021, December 27). Improvement of Liver Function in Liver Cirrhosis Patients After Autologous Mesenchymal Stem Cell Injection:a Phase I-II Clinical Trial, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT00420134."},{"key":"ref_242","unstructured":"Royan, I. (2022, January 20). Transplantation of Autologous Mesenchymal Stem Cell in Decompensate Cirrhotic Patients With Pioglitazone, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT01454336."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1182\/blood-2004-04-1559","article-title":"Human mesenchymal stem cells modulate allogeneic immune cell responses","volume":"105","author":"Aggarwal","year":"2005","journal-title":"Blood"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00535-019-01599-1","article-title":"The mesenchymal stem cell secretome as an acellular regenerative therapy for liver disease","volume":"54","author":"Driscoll","year":"2019","journal-title":"J. Gastroenterol."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1053\/j.gastro.2016.12.003","article-title":"Milk fat globule-EGF factor 8, secreted by mesenchymal stem cells, protects against liver fibrosis in mice","volume":"152","author":"An","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"4898152","DOI":"10.1155\/2018\/4898152","article-title":"Conditioned Medium from Human Amnion-Derived Mesenchymal Stem Cells Regulates Activation of Primary Hepatic Stellate Cells","volume":"2018","author":"Fu","year":"2018","journal-title":"Stem Cells Int."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-016-0792-1","article-title":"Mesenchymal stem cells and their secreted molecules predominantly ameliorate fulminant hepatic failure and chronic liver fibrosis in mice respectively","volume":"14","author":"Huang","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.7150\/thno.40122","article-title":"Mesenchymal stromal\/stem cell-derived extracellular vesicles in tissue repair: Challenges and opportunities","volume":"10","author":"Lorenowicz","year":"2020","journal-title":"Theranostics"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.3748\/wjg.v24.i23.2427","article-title":"Taking advantage of the potential of mesenchymal stromal cells in liver regeneration: Cells and extracellular vesicles as therapeutic strategies","volume":"24","author":"Fiore","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1089\/scd.2012.0395","article-title":"Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis","volume":"22","author":"Li","year":"2013","journal-title":"Stem Cells Dev."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-019-1539-8","article-title":"hUCMSC-extracellular vesicles downregulated hepatic stellate cell activation and reduced liver injury in S. japonicum-infected mice","volume":"11","author":"Dong","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1002\/jcp.26413","article-title":"Extracellular vesicles derived from human embryonic stem cell-MSCs ameliorate cirrhosis in thioacetamide-induced chronic liver injury","volume":"233","author":"Mardpour","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jhep.2007.07.006","article-title":"Grading and staging systems for inflammation and fibrosis in chronic liver diseases","volume":"47","author":"Goodman","year":"2007","journal-title":"J. Hepatol."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jhep.2014.02.031","article-title":"Image analysis of liver biopsy samples measures fibrosis and predicts clinical outcome","volume":"61","author":"Huang","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1080\/13543784.2020.1839888","article-title":"The nonalcoholic steatohepatitis (NASH) drug development graveyard: Established hurdles and planning for future success","volume":"29","author":"Drenth","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease\u2014A global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J. Hepatol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/9\/1500\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:04:32Z","timestamp":1760137472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/9\/1500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":256,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["cells11091500"],"URL":"https:\/\/doi.org\/10.3390\/cells11091500","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,29]]}}}